Nanoviricides Inc (AMEX:NNVC) Stock News, Headlines & Updates
Nanoviricides Inc Stock News from GuruFocus
- 1
Jul 23, 2025
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
ACCESSWIRE • 11:00am
NanoViricides (NNVC) Highlights Potential of Antiviral Drug NV-387 | NNVC Stock News
GuruFocus News • 8:02am
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value | NN
GuruFocus News • 7:46am
Jul 21, 2025
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
ACCESSWIRE • 7:00am
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides | NNVC Stock News
GuruFocus News • 5:46am
Jul 16, 2025
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
ACCESSWIRE • 11:00am
NanoViricides (NNVC) Advances MPox Treatment Amid WHO Alert | NNVC Stock News
GuruFocus News • 8:16am
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides | NNVC Stock News
GuruFocus News • 7:51am
Jul 14, 2025
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
ACCESSWIRE • 7:00am
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides | NNVC Stock News
GuruFocus News • 5:46am
Jul 01, 2025
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
ACCESSWIRE • 7:00am
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate | NNVC Stock News
GuruFocus News • 6:00am
Jun 18, 2025
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
ACCESSWIRE • 7:00am
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan | NNVC Stock News
GuruFocus News • 5:45am
Jun 04, 2025
NanoViricides (NNVC) Advances Measles Drug Development | NNVC Stock News
GuruFocus News • 8:18am
NanoViricides Measles Drug Development Animal Study is Imminent
ACCESSWIRE • 7:00am
NanoViricides Measles Drug Development Animal Study is Imminent | NNVC Stock News
GuruFocus News • 6:15am
May 28, 2025
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
ACCESSWIRE • 7:00am
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 | NNVC Stock News
GuruFocus News • 5:46am
May 22, 2025
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
ACCESSWIRE • 7:00am
May 16, 2025
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and
GuruFocus News • 5:45am
May 14, 2025
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
ACCESSWIRE • 7:00am
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution | NNVC Stock News
GuruFocus News • 5:45am
May 08, 2025
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
ACCESSWIRE • 7:00am
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo | NNVC Stock News
GuruFocus News • 5:47am
May 05, 2025
NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC | NNVC Stock News
GuruFocus News • 5:45am
Apr 29, 2025
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
ACCESSWIRE • 7:00am
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It | NNVC Stock News
GuruFocus News • 5:45am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news